pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
Oct 2, 26
Bayer unpacks plans for $2.2B manufacturing site in Ohio
endpoints
Oct 2, 26
Geographic atrophy biotech Aviceda to shut down after Phase 2 fail
endpoints
Oct 2, 26
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
Oct 1, 26
As CDC redesigns annual health survey, it removes questions about disabilities
stat
Oct 1, 26
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
biospace
Sep 30, 26
VertigoDx on firm ground with FDA greenlight for vertigo diagnostic system
fiercebiotech
Sep 29, 26
Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing
endpoints
Sep 28, 26
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
Sep 28, 26
Kodiak skyrockets on positive study data for 2 eye drugs
biopharma dive
Sep 28, 26
Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
endpoints
Sep 28, 26
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
biospace
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
fiercebiotech
Sep 25, 26
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
stat
Sep 25, 26
After COVID, biomanufacturing tackles preparedness and commercialization challenges
biospace
Sep 25, 26
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Sep 24, 26
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
Sep 24, 26
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
Sep 24, 26
Merck’s return to ophthalmology snags first success
endpoints
Sep 24, 26
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
biospace
Sep 24, 26
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
Sep 24, 26
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
Sep 23, 26
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 22, 26
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
Sep 22, 26
STAT+: Epic’s mortality model, and Omada’s future products
stat
Sep 21, 26
Beacon eye gene therapy hits mark in late-stage study
biopharma dive
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Novo aims to diversify with new pipeline assets and bolt-on deals
endpoints
← prev
page 6 of 14
next →